D. Schwartz

R. Korngold, D. Schwartz, S. Iyengar, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A peptide enzyme linked immunosorbent assay (ELISA) for the detection of human immunodeficiency virus type-2 (HIV-2) antibodies: an evaluation on polymerase chain reaction (PCR) confirmed samples.

M. Jesudason, S. Ramalingam, G. Sridharan, 2001, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network.

R. Belshe, B. Graham, P. Wright, 1993, The Journal of infectious diseases.

Augmentation of Human Immunodeficiency Virus Type 1 Neutralizing Antibody by Priming with gp160 Recombinant Vaccinia and Boosting with gp160 in Vaccinia-Naive Adults

R. Belshe, B. Graham, P. Wright, 1993 .

Evaluation of canarypox-induced CD8(+) responses following immunization by measuring the effector population IFNgamma production.

P. Caudrelier, J. Andrews, T. Evans, 2001, Immunology letters.

Safety and Immunogenicity of a Candidate HIV-1 Vaccine in Healthy Adults: Recombinant Glycoprotein (rgp) 120: A Randomized, Double-Blind Trial

Thomas Matthews, Michael Keefer, M. McElrath, 1996, Annals of Internal Medicine.

HIV‐1 recombinant gp160 vaccine given in accelerated dose schedules

D. Stablein, R. Belshe, B. Graham, 1994, Clinical and experimental immunology.

Increase in plasma IL-10 levels and rapid loss of CD4+ T cells among HIV-infected individuals in south India

D. Mathai, P. Srikanth, G. Sridharan, 2000, International Journal of STD and AIDS.

T cell-tropic HIV gp120 mediates CD4 and CD8 cell chemotaxis through CXCR4 independent of CD4: implications for HIV pathogenesis.

James E. K. Hildreth, D. Schwartz, S. Iyengar, 1999, Journal of immunology.

Pathogenesis Independent of CD 4 : Implications for HIV CD 8 Cell Chemotaxis through CXCR 4 T Cell-Tropic HIV gp 120 Mediates CD 4 and

D. Schwartz, H. S. Iyengar, 1999 .

Priming of virus-immune memory T cells in newborn mice

N. Greenspan, P. Doherty, J. Hurwitz, 1984, Infection and immunity.

Failure of Inositol Trispyrophosphate to Enhance Highly Effective Radiotherapy of GL261 Glioblastoma in Mice.

D. Schwartz, S. Iyengar, 2017, Anticancer research.

Recognition of Apoptotic Cells by Viruses and Cytolytic Lymphocytes: Target Selection in the Fog of War

D. Schwartz, S. Iyengar, 2020, Viral immunology.

Failure of insulin-like growth factor type I to suppress HIV type 1 in adult or umbilical cord mononuclear blood cells.

U. Sharma, Haifeng Song, D. Schwartz, 1997, AIDS research and human retroviruses.

Development and Loss of Virus‐Specific Thymic Competence in Bone Marrow Radiation Chimeras and Normal Mice

P. Doherty, R. Korngold, D. Schwartz, 1981, Immunological reviews.

Human erythrocytes bearing electroinserted CD4 neutralize infection in vitro by primary isolates of human immunodeficiency virus type 1.

C. Flexner, D. Norse, U. Sharma, 1996, Blood.

Virus-immune and alloreactive response characteristics of thymocytes and spleen cells from young mice.

P. Doherty, D. Schwartz, 1981, Journal of immunology.

HIV-1 p17 synthetic peptide vaccine HGP-30: induction of immune response in human subjects and preliminary evidence of protection against HIV challenge in SCID mice.

J. Kahn, B. Gazzard, M. Youle, 1995, Cellular and molecular biology.

Risk Associated HIV-1 Cross-Clade Resistance of Whole Peripheral Blood Mononuclear Cells From Exposed Uninfected Individuals With Wild-Type CCR5

D. Schwartz, G. J. Finny, R. John, 2004, Journal of acquired immune deficiency syndromes.

Targeted transduction of CD34+ cells by transdominant negative Rev-expressing retrovirus yields partial anti-HIV protection of progeny macrophages.

R. Morgan, G. Bauer, B. Davis, 1998, Human Gene Therapy.

Acquisition of CD4-Dependence by CD4-Independent SIV Passaged in Human Peripheral Blood Mononuclear Cells

D. Schwartz, S. Iyengar, 2012, Retrovirology.

In vivo fate of HIV-1-infected T cells: Quantitative analysis of the transition to stable latency

Robert F. Siliciano, R. Siliciano, J. Margolick, 1995, Nature Medicine.

Detection and Qualification of Human Immunodeficiency Virus RNA in Patient Serum by Use of the Polymerase Chain Reaction

D. Katzenstein, T. Merigan, M. Holodniy, 1991 .

Detection and quantification of human immunodeficiency virus RNA in patient serum by use of the polymerase chain reaction.

D. Katzenstein, T. Merigan, M. Holodniy, 1991, The Journal of infectious diseases.

Safety and Immunogenicity of a High‐Titered Canarypox Vaccine in Combination With rgp120 in a Diverse Population of HIV‐1‐Uninfected Adults: AIDS Vaccine Evaluation Group Protocol 022A

M. Hudgens, D. Montefiori, M. Mulligan, 2002, Journal of acquired immune deficiency syndromes.

Extensive evaluation of a seronegative participant in an HIV-1 vaccine trial as a result of false-positive PCR

O. Laeyendecker, D. Schwartz, R. Castillo, 1997, The Lancet.

Defective accessory genes in a human immunodeficiency virus type 1-infected long-term survivor lacking recoverable virus

D. Birx, M. Busch, N. Michael, 1995, Journal of virology.

Adherence of human immunodeficiency virus-infected lymphocytes to fetal placental cells: a model of maternal --> fetal transmission.

U. Sharma, D. Schwartz, E. Perlman, 1995, Proceedings of the National Academy of Sciences of the United States of America.

Negative selection experiments support the idea that T-T help is required for the H-Y specific cytotoxic T cell response.

J. Bennink, P. Doherty, D. Schwartz, 1981, Cellular immunology.

A Phase I safety and immunogenicity trial of UBI microparticulate monovalent HIV-1 MN oral peptide immunogen with parenteral boost in HIV-1 seronegative human subjects.

J. Lambert, M. Mulligan, W. Koff, 2001, Vaccine.

Absent or rare human immunodeficiency virus infection of bone marrow stem/progenitor cells in vivo

T. Merigan, A. Zander, B. Davis, 1991, Journal of virology.

QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans.

D. Montefiori, M. Mulligan, R. Belshe, 2001, Vaccine.

Decrease in HIV provirus in peripheral blood mononuclear cells during zidovudine and human rIL-2 administration.

D. Katzenstein, T. Merigan, M. Holodniy, 1992, Journal of acquired immune deficiency syndromes.

Chemokine-independent in vitro resistance to human immunodeficiency virus (HIV-1) correlating with low viremia in long-term and recently infected HIV-1-positive persons.

U. Sharma, G. Sridharan, D. Schwartz, 1997, The Journal of infectious diseases.

V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Trials Network.

D. Montefiori, B. Graham, L. Cavacini, 1993, The Journal of clinical investigation.

Safety and efficacy of polyethylene glycol-modified interleukin-2 and zidovudine in human immunodeficiency virus type 1 infection: a phase I/II study.

T. Merigan, J. Montoya, D. Schwartz, 1993, The Journal of infectious diseases.

Actin-Dependent Receptor Colocalization Required for Human Immunodeficiency Virus Entry into Host Cells

David H. Schwartz, D. Schwartz, S. Iyengar, 1998, Journal of Virology.

Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group, and the Correlates of HIV Immune Protection Group.

B. Korber, D. Montefiori, Steven Wolinsky, 1998, The Journal of infectious diseases.

Selective transmission of human immunodeficiency virus type 1 variants to SCID mice reconstituted with human peripheral blood monoclonal cells

J. Margolick, D. Vlahov, A. Templeton, 1996, Journal of virology.

Appendix A A Technical Review of the Evidence for Adverse Reactions to HIV Vaccines

D. Schwartz, 1995 .

Induction of neonatal tolerance to H-2k in B6 mice does not allow the emergence of T cells specific for H-2k plus vaccinia virus

P. Doherty, D. Schwartz, 1982, The Journal of experimental medicine.

Genetic and immunologic characterization of viruses infecting MN-rgp120-vaccinated volunteers.

T. Wrin, G. Nakamura, D. Francis, 1997, The Journal of infectious diseases.

Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.

J. Mascola, D. Burke, M. McElrath, 1996, The Journal of infectious diseases.

Vaccine-specific antibody responses induced by HIV-1 envelope subunit vaccines.

B. Graham, S. Pincus, R. Ireland, 1997, Journal of Immunology.

Differences in the antibody response to human immunodeficiency virus-1 envelope glycoprotein (gp160) in infected laboratory workers and vaccinees.

W. Blattner, B. Graham, S. Pincus, 1993, The Journal of clinical investigation.

Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group.

R. Siliciano, E. Paoletti, J. Mascola, 1998, The Journal of infectious diseases.

Modeling partially effective HIV vaccines in vitro.

S. Self, D. Schwartz, R. John, 2004, The Journal of infectious diseases.

Toward genetic rationalization of antiretroviral therapy for HIV.

D. Schwartz, S. Iyengar, 2005, AIDS.

Absence of recoverable infectious virus and unique immune responses in an asymptomatic HIV+ long-term survivor.

J. Lieberman, J. Margolick, T. Quinn, 1994, AIDS research and human retroviruses.

A novel factor produced by placental cells with activity against HIV-1.

O. Laeyendecker, U. Sharma, X. Yu, 1998, Journal of immunology.

Molecular Confirmation of Human Immunodeficiency Virus (HIV) Type 2 in HIV-Seropositive Subjects in South India

M. Jesudason, S. Ramalingam, G. Sridharan, 2000, Clinical Diagnostic Laboratory Immunology.

HIV-2 status in southern India.

G. Sridharan, S. Ramalingam, T. John, 1999, Transactions of the Royal Society of Tropical Medicine and Hygiene.

Antibody responses to Haemophilus influenzae type B vaccines in men with human immunodeficiency virus infection.

D. Vlahov, R. Chaisson, M. Steinhoff, 1991, The New England journal of medicine.

Induction of HIV-1-neutralising and syncytium-inhibiting antibodies in uninfected recipients of HIV-1IIIB rgp120 subunit vaccine

R. Siliciano, D. Stablein, R. Belshe, 1993, The Lancet.

Lack of correlation between the number of circulating B cells and the concentration of serum antibodies reactive with the HIV-1 envelope glycoprotein.

D. Klinman, J. Conover, D. Schwartz, 1994, Journal of acquired immune deficiency syndromes.

Antibody to human immunodeficiency virus type 1 (HIV-1) gp160 in mucosal specimens of asymptomatic HIV-1-infected volunteers parenterally immunized with an experimental recombinant HIV-1 IIIB gp160 vaccine. The National Institute of Allergy and Infectious Diseases-sponsored AIDS Vaccine Evaluation G

J. Lambert, M. Winget, M. Wolff, 1997, Clinical and diagnostic laboratory immunology.

Safety profile of phase I and II preventive HIV type 1 envelope vaccination: experience of the NIAID AIDS Vaccine Evaluation Group.

M. L. Clements-Mann, R. Belshe, B. Graham, 1997, AIDS research and human retroviruses.

HIV Vaccine toward the Development of the Next Generation Epitope Enhancement of a CD4 HIV Epitope

J. Berzofsky, K. Thomas, P. Sarobe, 2012 .

Generation HIV Vaccine toward the Development of the Next Epitope Enhancement of a CD4 HIV Epitope

J. Berzofsky, P. Sarobe, C. D. Pendleton, 2006 .

Utility of various commercially available human immunodeficiency virus (HIV) antibody diagnostic kits for use in conjunction with efficacy trials of HIV-1 vaccines

S. Winston, S. Harkonen, D. Schwartz, 1995, Clinical and Diagnostic Laboratory Immunology.

Rapid communication: development of in vitro resistance to macrophage-tropic- and T-cell-line-adapted HIV-1 strains among HIV-positive volunteers treated with highly active antiretroviral therapy.

D. Schwartz, B. C. Turner, R. Castillo, 2000, Journal of acquired immune deficiency syndromes.

Resistance to human immunodeficiency virus type 1 in vitro as a surrogate of vaccine-induced protective immunity.

L. Carruth, K. Weinhold, P. Kanki, 2000, The Journal of infectious diseases.

Safety and Effects of Interleukin‐2 Plus Zidovudine in Asymptomatic Individuals Infected with Human Immunodeficiency Virus

T. Merigan, D. Schwartz, G. Skowron, 1991, Journal of acquired immune deficiency syndromes.

A phase II study of two HIV type 1 envelope vaccines, comparing their immunogenicity in populations at risk for acquiring HIV type 1 infection. AIDS Vaccine Evaluation Group.

D. Montefiori, D. Stablein, M. McElrath, 2000, AIDS research and human retroviruses.

Diagnosis of human immunodeficiency virus infection using citrated whole blood

C. Flexner, H. Farzadegan, U. Sharma, 1997, Clinical and diagnostic laboratory immunology.

Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. A randomized, double-blind trial. NIAID AIDS Vaccine Evaluation Group.

B. Graham, F. Sinangil, J. Esterlitz, 1996, Annals of internal medicine.

HIV-2 subtype circulating in India (south).

M. Jesudason, S. Ramalingam, G. Sridharan, 2003, Journal of acquired immune deficiency syndromes.

Advancing AIDSVAX to phase 3. Safety, immunogenicity, and plans for phase 3.

R. Belshe, D. Francis, P. Berman, 1998, AIDS research and human retroviruses.

A vaccinia-gp160-based vaccine but not a gp160 protein vaccine elicits anti-gp160 cytotoxic T lymphocytes in some HIV-1 seronegative vaccinees.

J. Lieberman, M. Perales, D. Schwartz, 1995, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

Vaccination of vaccinia-naive adults with human immunodeficiency virus type 1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial. The AIDS Vaccine Clinical Trials Network.

D. Montefiori, N. Roberts, J. Lambert, 1992, The Journal of infectious diseases.